Recce recruits patients for phase one RECCE® 327 trial

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF)'s James Graham talks to Proactive after 10 patients were enrolled in the company's phase one intravenous clinical trial for its lead compound, RECCE® 327. He says the drug candidate is the only clinical-stage antibiotic in the world being developed for sepsis — the largest unmet medical need in human health — meaning the compound has substantial upside potential.